Piper Jaffray Reiterates Upbeat View on GW Pharmaceuticals PLC- ADR Following NYU Epilepsy Treatment Course
In a research report published today, Piper Jaffray analyst Joshua Schimmer offered some favorable commentary on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) after attending a one-day course at NYU covering cannabinoids for the treatment of epilepsy. Schimmer reiterated an Overweight rating on with a price target of $147.00. Shares of GWPH are currently trading at $120.43, down $3.77, or -3.04%.
After attending the course, the analyst explained that “[He] continue[s] to believe GW is uniquely positioned to benefit from the growing enthusiasm and emerging science for the wide range of potential conditions given its extensive involvement and expertise.” Furthermore, Schimmer expressed that GWPH remains the firm’s top mid-cap pick going into a data-rich 2H.
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joshua Schimmer has a total average return of 11.5% and a 61.0% success rate. Schimmer has a 49.8% average return when recommending GWPH, and is ranked #306 out of 3681 analysts.